Mesoblast Limited (MESO) Stock

About Mesoblast Limited

Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.

Mesoblast Limited is headquartered in AU.

Mesoblast Limited (MESO) stock trades at $18.24 with a market capitalization of $2.36B. The stock is valued at a negative price-to-earnings (P/E) ratio of -25.86, reflecting a net loss over the last twelve months, price-to-book of 4.28, price-to-sales of 37.63. Over the past 52 weeks the stock has ranged between $11.05 and $21.50, and currently trades 15.2% below its 52-week high.

On profitability, Mesoblast Limited generates a return on equity (ROE) of -16.10% (negative, reflecting a net loss), return on capital employed of -22.29%, an operating margin of -223.08%, a net profit margin of -144.33%.

Official website: www.mesoblast.com

Mesoblast Limited by the numbers, 2016–2025

Between 2016 and 2025 Mesoblast Limited reported revenue of $43.0M rising to $17.0M, a change of -60.5% across 10 years. Compounded, revenue has grown -11.9% a year over five years, 19.4% over three, 183.3% over the last twelve months. Net profit fell to $-102.0M.

Operating margin went from -131.3% in 2016 to -363.1% in 2025, a fall of 231.7 percentage points. The most recent net margin is -144.33%. On a trailing twelve-month basis to Dec '25, revenue is $66.0M and net profit $-94.0M.

Borrowings stand at $128.0M, cash on hand is $129.6M, cash from operations was $-50.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -17.4% over five years, and was -17.1% in the most recent year.

The share price itself has compounded at 5.4% a year over five years, 23.9% over three, 66.4% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Mesoblast Limited (MESO) — frequently asked questions